MeSH term
Frequency | Condition_Probility | Aged | 122 | 0.0 |
Humans | 1629 | 0.0 |
Risk | 20 | 2.0 |
Time Factors | 61 | 0.0 |
Adult | 390 | 0.0 |
Disease Outbreaks | 2 | 3.0 |
Female | 570 | 0.0 |
Male | 558 | 0.0 |
Middle Aged | 259 | 0.0 |
English Abstract | 124 | 1.0 |
Sinusitis/genetics/*immunology | 2 | 100.0 |
Antilymphocyte Serum/therapeutic use | 2 | 9.0 |
Confidence Intervals | 4 | 1.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Follow-Up Studies | 36 | 1.0 |
Incidence | 15 | 1.0 |
Methylprednisolone/therapeutic use | 2 | 4.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Retrospective Studies | 50 | 1.0 |
Risk Factors | 55 | 0.0 |
Survival Rate | 20 | 0.0 |
Treatment Failure | 6 | 2.0 |
*Alleles | 132 | 9.0 |
Cells, Cultured | 43 | 0.0 |
HLA-B Antigens/*genetics/immunology | 21 | 77.0 |
Molecular Sequence Data | 277 | 0.0 |
Multigene Family | 8 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 63 | 0.0 |
Sequence Homology | 3 | 0.0 |
Adolescent | 181 | 1.0 |
Comparative Study | 190 | 0.0 |
Gene Frequency/genetics | 10 | 2.0 |
HLA-B Antigens/*genetics | 192 | 71.0 |
Haplotypes | 110 | 5.0 |
Research Support, Non-U.S. Gov't | 790 | 0.0 |
Thailand | 8 | 5.0 |
Alleles | 295 | 3.0 |
Bone Marrow Transplantation | 11 | 4.0 |
Evaluation Studies | 7 | 1.0 |
*Genes, MHC Class I | 84 | 32.0 |
HLA-B Antigens/analysis/*genetics/immunology | 3 | 75.0 |
Polymerase Chain Reaction/methods | 31 | 2.0 |
Quality Control | 5 | 2.0 |
Registries | 21 | 9.0 |
Sensitivity and Specificity | 14 | 0.0 |
Sequence Analysis, DNA/methods | 3 | 3.0 |
Animals | 128 | 0.0 |
Biopsy | 5 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 4 | 1.0 |
Immunoenzyme Techniques | 17 | 0.0 |
Mice | 69 | 0.0 |
Mice, SCID | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 376 | 0.0 |
Genotype | 91 | 0.0 |
HLA Antigens/*genetics | 197 | 23.0 |
HLA-B Antigens/genetics | 100 | 47.0 |
Oligonucleotides/genetics | 3 | 8.0 |
Polymerase Chain Reaction | 113 | 0.0 |
Evolution, Molecular | 12 | 1.0 |
Gene Frequency | 188 | 3.0 |
*Polymorphism, Genetic | 85 | 1.0 |
HLA-B Antigens/genetics/*immunology | 14 | 73.0 |
Histocompatibility Antigens Class I/immunology | 10 | 9.0 |
Ligands | 11 | 0.0 |
Peptides/immunology | 4 | 2.0 |
Demography | 2 | 1.0 |
Europe | 9 | 3.0 |
Graft Survival | 56 | 14.0 |
Immunosuppression | 8 | 4.0 |
*Registries | 4 | 8.0 |
*Tissue and Organ Procurement | 4 | 40.0 |
Treatment Outcome | 22 | 0.0 |
United States | 17 | 2.0 |
Genetic Predisposition to Disease | 48 | 2.0 |
HLA-DR Antigens/genetics | 34 | 8.0 |
Histocompatibility Antigens Class I/*genetics | 87 | 26.0 |
Histocompatibility Testing | 170 | 21.0 |
Polymorphism, Genetic | 107 | 2.0 |
Tumor Necrosis Factor-alpha/genetics | 14 | 6.0 |
Child | 154 | 1.0 |
HLA-B35 Antigen/*genetics | 2 | 66.0 |
Linkage Disequilibrium | 47 | 5.0 |
Phenotype | 129 | 1.0 |
Age of Onset | 9 | 0.0 |
Diabetes Mellitus, Type 1/ethnology/*genetics | 3 | 27.0 |
Ethnic Groups/genetics | 8 | 4.0 |
Genetic Predisposition to Disease/*genetics | 7 | 1.0 |
Anemia, Aplastic/therapy | 2 | 13.0 |
Bone Marrow Transplantation/*immunology | 17 | 14.0 |
Genetic Diseases, Inborn/therapy | 2 | 33.0 |
HLA-A Antigens/*genetics | 49 | 24.0 |
HLA-DR Antigens/*genetics | 36 | 6.0 |
Immunosuppressive Agents/therapeutic use | 11 | 5.0 |
Recurrence | 14 | 1.0 |
*Tissue Donors | 20 | 14.0 |
Major Histocompatibility Complex/*immunology | 3 | 7.0 |
Antibodies, Monoclonal/immunology | 25 | 1.0 |
HLA Antigens/genetics/*metabolism | 2 | 16.0 |
Histocompatibility Antigens Class I/genetics/*metabolism | 2 | 6.0 |
*Algorithms | 4 | 6.0 |
Antibody Specificity | 33 | 2.0 |
HLA Antigens/*genetics/immunology | 11 | 26.0 |
HLA-A Antigens/genetics | 49 | 31.0 |
HLA-C Antigens/genetics | 29 | 30.0 |
Histocompatibility Testing/*methods | 43 | 28.0 |
Base Sequence | 235 | 0.0 |
DNA Primers | 23 | 0.0 |
European Continental Ancestry Group/genetics | 27 | 4.0 |
HLA-C Antigens/*genetics | 32 | 47.0 |
Case-Control Studies | 24 | 0.0 |
China/ethnology | 2 | 1.0 |
DNA/analysis | 23 | 2.0 |
Ethnic Groups | 7 | 2.0 |
*Gene Frequency | 34 | 6.0 |
*Genetic Predisposition to Disease | 20 | 1.0 |
Questionnaires | 4 | 0.0 |
Down-Regulation | 16 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
HLA Antigens/*immunology | 63 | 22.0 |
HLA-C Antigens/*immunology | 5 | 35.0 |
Histocompatibility Antigens Class I/*immunology | 17 | 15.0 |
Killer Cells, Natural/immunology | 11 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 26 | 6.0 |
Tumor Cells, Cultured | 57 | 0.0 |
Aged, 80 and over | 14 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Histocompatibility Antigens Class I/*metabolism | 8 | 8.0 |
Prospective Studies | 28 | 0.0 |
Continental Population Groups/genetics | 3 | 3.0 |
Dideoxynucleosides/*adverse effects | 2 | 100.0 |
Genetic Markers | 34 | 1.0 |
HIV-1 | 2 | 1.0 |
Predictive Value of Tests | 5 | 0.0 |
Reverse Transcriptase Inhibitors/*adverse effects | 2 | 20.0 |
*Variation (Genetics) | 23 | 2.0 |
Introns | 8 | 0.0 |
*Linkage Disequilibrium | 12 | 7.0 |
Microsatellite Repeats | 15 | 1.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Promoter Regions (Genetics)/*genetics | 6 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 29 | 8.0 |
Killer Cells, Natural/*immunology | 27 | 5.0 |
Lymphocyte Activation | 26 | 0.0 |
Neoplasms/*immunology | 6 | 5.0 |
Flow Cytometry | 28 | 0.0 |
Gene Expression Regulation, Neoplastic/*immunology | 3 | 20.0 |
Abortion, Spontaneous/immunology | 2 | 25.0 |
Antibodies, Monoclonal/pharmacology | 5 | 0.0 |
*Antigen Presentation | 4 | 2.0 |
K562 Cells | 5 | 1.0 |
*Lectins, C-Type | 6 | 3.0 |
Macromolecular Substances | 12 | 0.0 |
Pregnancy | 56 | 0.0 |
Cell Line | 119 | 0.0 |
Genetics, Population | 18 | 4.0 |
Homozygote | 40 | 2.0 |
Italy | 11 | 1.0 |
*Microsatellite Repeats | 7 | 3.0 |
Computer Simulation | 5 | 1.0 |
Exons/genetics | 15 | 1.0 |
Genes, MHC Class I/*genetics | 24 | 33.0 |
Heterozygote Detection | 7 | 1.0 |
Kinetics | 17 | 0.0 |
*Models, Genetic | 4 | 3.0 |
Oligonucleotide Probes/genetics | 3 | 2.0 |
Pedigree | 98 | 1.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Templates, Genetic | 2 | 1.0 |
African Continental Ancestry Group/*genetics | 7 | 2.0 |
Alu Elements/*genetics | 3 | 9.0 |
Polymorphism, Genetic/*genetics | 14 | 1.0 |
Sequence Homology, Nucleic Acid | 50 | 1.0 |
Argentina | 4 | 8.0 |
Brazil | 13 | 5.0 |
Indians, South American/*genetics | 17 | 26.0 |
Phylogeny | 16 | 1.0 |
Histocompatibility Antigens Class I/analysis | 3 | 3.0 |
Interferon Type II/pharmacology | 15 | 2.0 |
HLA-B Antigens/*analysis/*genetics | 2 | 100.0 |
Nucleic Acid Hybridization | 26 | 1.0 |
Sequence Alignment | 31 | 0.0 |
Sequence Analysis, DNA | 45 | 1.0 |
HLA Antigens/*analysis | 88 | 20.0 |
HLA-A Antigens/analysis | 20 | 21.0 |
HLA-B Antigens/analysis | 34 | 31.0 |
HLA-C Antigens/analysis | 10 | 20.0 |
Kidney Transplantation | 10 | 8.0 |
Polymerase Chain Reaction/*methods | 20 | 3.0 |
Sampling Studies | 3 | 1.0 |
DNA | 14 | 1.0 |
Exons | 27 | 0.0 |
Chi-Square Distribution | 16 | 2.0 |
Japan | 33 | 2.0 |
Celiac Disease/*genetics | 5 | 17.0 |
HLA-DQ Antigens/*genetics | 16 | 4.0 |
Histocompatibility Testing/methods | 8 | 18.0 |
*Genetics, Population | 8 | 2.0 |
Tunisia | 3 | 7.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
DNA Probes, HLA/*genetics | 3 | 75.0 |
DNA Primers/genetics | 11 | 0.0 |
Exons/*genetics | 6 | 1.0 |
Germany | 5 | 1.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Double-Blind Method | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 12 | 0.0 |
Serologic Tests | 3 | 3.0 |
CD8-Positive T-Lymphocytes/immunology | 3 | 0.0 |
HLA-B27 Antigen/*genetics | 9 | 47.0 |
Colitis, Ulcerative/*genetics | 3 | 11.0 |
European Continental Ancestry Group | 18 | 2.0 |
Haplotypes/genetics | 26 | 4.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 7 | 12.0 |
HLA-B8 Antigen/genetics | 8 | 44.0 |
HLA-DR3 Antigen/genetics | 5 | 20.0 |
Major Histocompatibility Complex/*genetics/immunology | 3 | 33.0 |
Chorionic Villi/immunology | 2 | 15.0 |
Histocompatibility Antigens Class I/*analysis | 9 | 19.0 |
*Immune Tolerance | 4 | 2.0 |
Immunity, Cellular | 12 | 1.0 |
Lymphocytes/immunology | 23 | 5.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Trophoblasts/immunology | 5 | 15.0 |
ATP-Binding Cassette Transporters/*genetics | 2 | 0.0 |
Child, Preschool | 66 | 0.0 |
*Cysteine Endopeptidases | 2 | 4.0 |
Korea | 12 | 5.0 |
*Multienzyme Complexes | 2 | 2.0 |
Proteins/*genetics | 8 | 0.0 |
Chronic Disease | 12 | 0.0 |
Remission Induction | 2 | 0.0 |
Reoperation | 9 | 6.0 |
Behcet Syndrome/*genetics | 12 | 52.0 |
Chromosome Mapping | 84 | 1.0 |
*Chromosomes, Human, Pair 6 | 11 | 4.0 |
Lod Score | 8 | 0.0 |
Microsatellite Repeats/genetics | 7 | 1.0 |
Turkey | 3 | 2.0 |
Amino Acid Sequence | 154 | 0.0 |
Amino Acid Substitution | 8 | 0.0 |
*Bone Marrow Transplantation | 17 | 4.0 |
HLA-B Antigens/chemistry/*genetics | 7 | 77.0 |
*Hematopoietic Stem Cell Transplantation | 4 | 1.0 |
Minority Groups | 2 | 28.0 |
Models, Molecular | 18 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
Variation (Genetics) | 23 | 1.0 |
HLA Antigens/*genetics/*immunology | 3 | 50.0 |
HLA-A Antigens/genetics/immunology | 7 | 35.0 |
HLA-B Antigens/genetics/immunology | 11 | 44.0 |
HLA-C Antigens/genetics/immunology | 5 | 35.0 |
HLA-DQ Antigens/genetics/immunology | 2 | 10.0 |
HLA-DR Antigens/genetics/immunology | 5 | 15.0 |
Asian Continental Ancestry Group/genetics | 14 | 4.0 |
HLA-DQ Antigens/genetics | 19 | 7.0 |
5' Flanking Region/genetics | 2 | 2.0 |
Behcet Syndrome/*genetics/*immunology | 4 | 100.0 |
Enhancer Elements (Genetics)/genetics | 2 | 2.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 17 | 2.0 |
Epitopes/*immunology | 10 | 4.0 |
HLA-B Antigens/immunology | 24 | 38.0 |
Protein Denaturation | 2 | 0.0 |
beta 2-Microglobulin/*metabolism | 4 | 9.0 |
Acute Disease | 16 | 0.0 |
Cadaver | 35 | 14.0 |
*Graft Survival | 30 | 20.0 |
HLA Antigens | 27 | 20.0 |
Survival Analysis | 14 | 0.0 |
Graft Rejection/*immunology | 7 | 8.0 |
HLA-A Antigens/*immunology | 16 | 18.0 |
HLA-B Antigens/*immunology | 27 | 44.0 |
HLA-DR Antigens/*immunology | 15 | 11.0 |
*Histocompatibility Testing | 53 | 25.0 |
*Keratoplasty, Penetrating | 2 | 33.0 |
Odds Ratio | 12 | 1.0 |
Proportional Hazards Models | 8 | 1.0 |
*Maternal-Fetal Exchange | 3 | 8.0 |
Antibodies, Monoclonal | 27 | 1.0 |
Disease Progression | 9 | 0.0 |
Genes, MHC Class I | 22 | 17.0 |
Genes, MHC Class II | 25 | 10.0 |
Histocompatibility Antigens Class II/*analysis | 8 | 7.0 |
Immunohistochemistry | 12 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Gene Expression | 12 | 0.0 |
*Genes, MHC Class II | 31 | 10.0 |
Hela Cells | 10 | 0.0 |
*Nuclear Proteins | 4 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
Transcription, Genetic | 16 | 0.0 |
HLA-B8 Antigen/*genetics | 6 | 50.0 |
HLA-DR3 Antigen/*genetics | 6 | 20.0 |
*Haplotypes | 22 | 8.0 |
Sequence Homology, Amino Acid | 23 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 3 | 2.0 |
*DNA Methylation | 2 | 0.0 |
DNA Primers/chemistry | 14 | 1.0 |
Gene Deletion | 3 | 0.0 |
Histocompatibility Antigens Class I/*genetics/metabolism | 3 | 15.0 |
Loss of Heterozygosity | 2 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
HLA Antigens/*analysis/immunology | 6 | 33.0 |
Histocompatibility Antigens Class II/analysis | 14 | 7.0 |
*Immunity | 2 | 4.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Echocardiography | 4 | 1.0 |
HLA-A Antigens/immunology | 22 | 31.0 |
HLA-DR Antigens/immunology | 15 | 7.0 |
Heart Valve Prosthesis Implantation | 2 | 15.0 |
Histocompatibility/*immunology | 5 | 33.0 |
Transplantation, Homologous/immunology | 4 | 9.0 |
Gene Expression Regulation | 11 | 0.0 |
Risk Assessment | 3 | 0.0 |
Tandem Repeat Sequences/*genetics | 2 | 2.0 |
Multigene Family/*immunology | 2 | 8.0 |
Cross Reactions/genetics | 3 | 42.0 |
HLA-B Antigens/*genetics/*immunology | 5 | 100.0 |
Reproducibility of Results | 8 | 0.0 |
HLA-B7 Antigen/chemistry/*genetics | 2 | 100.0 |
Immunophenotyping | 16 | 0.0 |
Introns/*genetics | 4 | 2.0 |
Cytotoxicity Tests, Immunologic | 28 | 6.0 |
HLA-B27 Antigen/genetics | 4 | 25.0 |
Spondylitis, Ankylosing/*genetics/immunology | 5 | 55.0 |
Antigens/immunology | 2 | 1.0 |
Immune Tolerance/*immunology | 2 | 4.0 |
Interleukin-2/pharmacology | 4 | 0.0 |
Liver Transplantation/*immunology | 2 | 6.0 |
Lymphocyte Culture Test, Mixed | 37 | 5.0 |
Monocytes/immunology | 6 | 1.0 |
T-Lymphocytes/immunology | 17 | 1.0 |
Tissue Donors | 41 | 15.0 |
African Continental Ancestry Group/genetics | 15 | 5.0 |
Ethnic Groups/*genetics | 11 | 5.0 |
Genetic Markers/genetics | 8 | 1.0 |
Haplotypes/*genetics | 17 | 8.0 |
Hispanic Americans/genetics | 3 | 7.0 |
Indians, North American/genetics | 8 | 20.0 |
Linkage Disequilibrium/genetics | 7 | 4.0 |
Colombia | 3 | 6.0 |
Complement 4a/genetics | 2 | 10.0 |
Complement 4b/genetics | 2 | 9.0 |
Complement Factor B/genetics | 9 | 12.0 |
Venezuela | 2 | 6.0 |
Gene Frequency/*genetics | 8 | 5.0 |
Genes, MHC Class II/*genetics | 6 | 8.0 |
Aging/*immunology | 2 | 1.0 |
HLA-A Antigens/*biosynthesis/genetics | 2 | 40.0 |
HLA-B Antigens/*biosynthesis/genetics | 2 | 50.0 |
Leukocytes/*immunology | 3 | 2.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Linkage Disequilibrium/*genetics | 3 | 4.0 |
Major Histocompatibility Complex/*genetics | 26 | 16.0 |
Variation (Genetics)/genetics | 3 | 1.0 |
HLA-A Antigens/*metabolism | 3 | 30.0 |
HLA-B Antigens/*metabolism | 9 | 75.0 |
HLA Antigens/*classification | 2 | 40.0 |
HLA-A Antigens/genetics/*immunology | 3 | 23.0 |
HLA-C Antigens/genetics/*immunology | 8 | 72.0 |
HLA-DR Antigens/genetics/*immunology | 2 | 6.0 |
Gene Frequency/*immunology | 3 | 37.0 |
Italy/epidemiology | 2 | 0.0 |
Models, Genetic | 12 | 0.0 |
*Sex Ratio | 3 | 30.0 |
Cell Line, Transformed | 38 | 2.0 |
HIV-1/*immunology | 3 | 0.0 |
HLA Antigens/immunology | 21 | 11.0 |
HLA-B35 Antigen/genetics | 4 | 66.0 |
HLA-B7 Antigen/immunology | 2 | 66.0 |
Receptors, Antigen, T-Cell/*immunology | 3 | 1.0 |
T-Lymphocytes, Cytotoxic/*immunology | 28 | 5.0 |
Severity of Illness Index | 4 | 0.0 |
Histocompatibility Antigens Class I/genetics | 13 | 13.0 |
Spondylitis, Ankylosing/*genetics | 14 | 51.0 |
DNA/*analysis | 4 | 1.0 |
Arthritis, Psoriatic/*genetics/immunology | 2 | 100.0 |
HLA-B Antigens/classification/genetics | 2 | 25.0 |
HT29 Cells | 2 | 1.0 |
Histocompatibility Antigens Class I/classification/*genetics | 3 | 27.0 |
Creatinine/blood | 8 | 2.0 |
Isoantibodies/*immunology | 4 | 10.0 |
Culture | 2 | 13.0 |
Prevalence | 4 | 0.0 |
Binding Sites | 17 | 0.0 |
Epitopes | 53 | 6.0 |
Lymphocytes/immunology/metabolism | 2 | 6.0 |
Peptide Library | 2 | 1.0 |
Protein Binding | 21 | 0.0 |
beta 2-Microglobulin/metabolism | 3 | 3.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Cohort Studies | 10 | 0.0 |
Epitopes/immunology | 10 | 1.0 |
*Homozygote | 6 | 3.0 |
Receptors, Immunologic/immunology | 3 | 2.0 |
Viral Load | 3 | 0.0 |
HLA-B Antigens/classification/*genetics | 11 | 64.0 |
Graft vs Host Disease/immunology | 2 | 6.0 |
Infant | 51 | 0.0 |
Survivors | 2 | 2.0 |
HLA-DR Antigens/classification/*genetics | 2 | 13.0 |
*Evolution, Molecular | 17 | 3.0 |
Indians, North American/*genetics | 8 | 9.0 |
Mexico | 8 | 8.0 |
Cytotoxicity Tests, Immunologic/*methods | 2 | 20.0 |
HLA-B Antigens/blood/*genetics | 2 | 100.0 |
Africa/ethnology | 3 | 6.0 |
HLA-DP Antigens/genetics | 5 | 10.0 |
Martinique | 2 | 66.0 |
Polymorphism, Genetic/genetics | 9 | 1.0 |
Age Factors | 25 | 1.0 |
Graft Survival/*physiology | 2 | 10.0 |
Sex Factors | 24 | 1.0 |
Tissue Donors/*statistics & numerical data | 3 | 42.0 |
Transplantation, Homologous | 32 | 4.0 |
Cyclosporine/therapeutic use | 4 | 5.0 |
Graft Survival/*immunology | 9 | 16.0 |
Kidney Transplantation/*immunology | 25 | 12.0 |
Nuclear Family | 6 | 2.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Oligonucleotide Probes | 16 | 2.0 |
Interferon Type II/*therapeutic use | 2 | 13.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
DNA, Complementary | 15 | 0.0 |
Gene Amplification | 4 | 0.0 |
Gene Duplication | 2 | 1.0 |
HLA-A Antigens/genetics/metabolism | 3 | 60.0 |
HLA-B Antigens/genetics/metabolism | 2 | 100.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Transfection | 41 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Lymphocyte Count | 3 | 0.0 |
Narcolepsy/*genetics | 3 | 37.0 |
Chromosome Mapping/methods | 2 | 1.0 |
Heterozygote | 20 | 0.0 |
Membrane Proteins/*genetics | 7 | 0.0 |
*Selection (Genetics) | 7 | 10.0 |
Antibodies, Monoclonal/*metabolism | 3 | 8.0 |
Clone Cells | 16 | 1.0 |
Multigene Family/immunology | 2 | 8.0 |
Polymorphism, Genetic/*immunology | 6 | 18.0 |
Variation (Genetics)/immunology | 2 | 28.0 |
Behcet Syndrome/epidemiology/*genetics/*immunology | 2 | 100.0 |
Genetic Markers/immunology | 6 | 31.0 |
Infant, Newborn | 18 | 0.0 |
Morocco/epidemiology | 2 | 40.0 |
Haplotypes/immunology | 5 | 35.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Reference Values | 10 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Haplotypes/*immunology | 7 | 28.0 |
Pilot Projects | 2 | 0.0 |
DNA/blood | 2 | 1.0 |
Epitopes/*genetics | 3 | 10.0 |
HIV Infections/genetics/immunology | 2 | 33.0 |
ATP-Binding Cassette Transporters/genetics/immunology | 2 | 66.0 |
Blotting, Western | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/immunology | 3 | 10.0 |
beta 2-Microglobulin/genetics/immunology | 2 | 40.0 |
*Blood Donors | 4 | 3.0 |
Fetal Blood/*immunology | 2 | 2.0 |
HLA-B Antigens/*genetics/isolation & purification | 3 | 100.0 |
Variation (Genetics)/*genetics | 6 | 2.0 |
West Indies/ethnology | 2 | 33.0 |
Trinucleotide Repeats/*genetics | 3 | 3.0 |
Family | 7 | 1.0 |
Gene Frequency/immunology | 6 | 40.0 |
Histocompatibility Antigens Class II/*genetics | 24 | 12.0 |
Linkage Disequilibrium/*immunology | 2 | 50.0 |
Graft Rejection/immunology | 7 | 10.0 |
HLA Antigens/metabolism | 3 | 9.0 |
Immunologic Memory | 2 | 0.0 |
Isoantigens/immunology | 4 | 4.0 |
Solubility | 6 | 0.0 |
Oligonucleotide Probes/*genetics | 3 | 60.0 |
Software | 3 | 1.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 17 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Molecular Weight | 11 | 0.0 |
Serotyping | 4 | 1.0 |
*Ethnic Groups | 4 | 3.0 |
Indians, Central American/*genetics | 2 | 16.0 |
Peptides/*immunology | 5 | 7.0 |
Sequence Analysis | 5 | 1.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
*Down-Regulation | 2 | 0.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
HLA-A2 Antigen/genetics | 3 | 21.0 |
HLA-B7 Antigen/genetics | 7 | 58.0 |
Melanoma/*genetics/immunology | 5 | 50.0 |
*Transcription, Genetic | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Recombination, Genetic | 50 | 5.0 |
Thiolester Hydrolases/genetics | 2 | 22.0 |
Algorithms | 4 | 1.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
Epitopes/genetics/immunology | 2 | 5.0 |
Fluorescent Antibody Technique | 9 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Histocompatibility | 28 | 26.0 |
Life Tables | 3 | 1.0 |
Multivariate Analysis | 11 | 0.0 |
Platelet Count | 2 | 0.0 |
Transplantation Conditioning | 2 | 3.0 |
United States/epidemiology | 3 | 0.0 |
Korea/epidemiology | 2 | 3.0 |
*Killer Cells, Natural | 2 | 9.0 |
Receptors, Immunologic/*genetics | 8 | 6.0 |
Cameroon | 2 | 9.0 |
HLA-A Antigens/*genetics/immunology | 5 | 26.0 |
Disease Susceptibility | 30 | 4.0 |
Spain | 13 | 3.0 |
Genes, Reporter | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Psoriasis/*genetics | 9 | 14.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Rabbits | 10 | 0.0 |
HLA-B Antigens/metabolism | 3 | 30.0 |
Cross Reactions | 40 | 4.0 |
Hematopoietic Stem Cells/*immunology | 4 | 2.0 |
Choriocarcinoma | 2 | 5.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Trophoblasts/cytology/*immunology | 2 | 28.0 |
Behcet Syndrome/ethnology/*genetics | 2 | 66.0 |
Japan/epidemiology | 5 | 1.0 |
Microsatellite Repeats/*genetics | 4 | 1.0 |
Europe/ethnology | 3 | 3.0 |
European Continental Ancestry Group/*genetics | 11 | 3.0 |
Computational Biology | 3 | 2.0 |
HLA Antigens/genetics | 50 | 16.0 |
DNA/genetics | 21 | 1.0 |
Conserved Sequence | 3 | 0.0 |
*HLA-B Antigens | 27 | 47.0 |
*Sequence Analysis, DNA | 6 | 8.0 |
*Chromosome Mapping | 26 | 1.0 |
Takayasu's Arteritis/*genetics | 6 | 75.0 |
Antigen-Antibody Reactions | 8 | 2.0 |
Binding Sites, Antibody | 7 | 2.0 |
Protein Conformation | 22 | 0.0 |
Electrophoresis, Agar Gel | 6 | 1.0 |
Slovakia | 2 | 9.0 |
Interferon-gamma, Recombinant/pharmacology | 5 | 3.0 |
Mutation | 12 | 0.0 |
*Major Histocompatibility Complex | 56 | 18.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
HLA-B Antigens/chemistry/*genetics/*immunology | 2 | 100.0 |
Histocompatibility Antigens Class I/genetics/*immunology | 6 | 22.0 |
Transcription, Genetic/immunology | 3 | 3.0 |
Chromosomes, Human, Pair 6 | 15 | 9.0 |
Linkage (Genetics) | 97 | 3.0 |
Major Histocompatibility Complex/genetics | 5 | 8.0 |
HLA Antigens/*analysis/genetics | 26 | 26.0 |
*Polymerase Chain Reaction | 6 | 2.0 |
Cluster Analysis | 3 | 1.0 |
HLA-B27 Antigen/analysis | 6 | 28.0 |
*Point Mutation | 3 | 0.0 |
Bone Marrow Transplantation/immunology | 3 | 8.0 |
Interferon Type I, Recombinant/pharmacology | 4 | 12.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
*Linkage (Genetics) | 28 | 2.0 |
Graft Survival/immunology | 12 | 22.0 |
HLA-A Antigens/*analysis | 11 | 30.0 |
HLA-B Antigens/*analysis | 22 | 43.0 |
HLA-DR Antigens/*analysis | 12 | 6.0 |
Prognosis | 30 | 0.0 |
*DNA | 2 | 6.0 |
Lymphatic Metastasis | 3 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 7 | 3.0 |
Random Allocation | 10 | 2.0 |
Belgium | 2 | 3.0 |
HLA-B27 Antigen/*analysis/*immunology | 2 | 100.0 |
Netherlands | 3 | 1.0 |
Reference Standards | 4 | 1.0 |
Evolution | 15 | 4.0 |
HLA-A2 Antigen/*genetics | 5 | 29.0 |
Histocompatibility Antigens Class I/genetics/*isolation & purification | 2 | 100.0 |
HLA-DQ Antigens/analysis | 5 | 10.0 |
Behcet Syndrome/*immunology | 4 | 18.0 |
Cell Division/immunology | 3 | 1.0 |
HLA-B Antigens/chemistry/*immunology | 3 | 100.0 |
Interleukin-2/secretion | 2 | 2.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Histocompatibility Antigens Class II/*genetics/*immunology | 2 | 100.0 |
Clone Cells/immunology | 6 | 3.0 |
*Cytotoxicity, Immunologic | 23 | 4.0 |
T-Lymphocytes, Cytotoxic/*immunology/pathology | 2 | 16.0 |
Bronchiolitis/*genetics | 3 | 60.0 |
Chromosomes, Human, Pair 6/*genetics | 5 | 3.0 |
Linkage (Genetics)/*genetics | 4 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
HLA-DR Antigens/analysis | 19 | 2.0 |
Matched-Pair Analysis | 4 | 4.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
HLA-A Antigens/biosynthesis/genetics | 2 | 33.0 |
HLA-B Antigens/biosynthesis/genetics | 2 | 50.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
*Kidney Transplantation | 53 | 10.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
*Transplantation, Homologous | 2 | 18.0 |
Netherlands/epidemiology | 4 | 3.0 |
China | 7 | 1.0 |
HLA-DR2 Antigen/genetics | 2 | 11.0 |
Major Histocompatibility Complex | 14 | 5.0 |
Skin/immunology/pathology | 2 | 4.0 |
HLA-B Antigens/*classification | 2 | 66.0 |
Terminology | 2 | 1.0 |
Chromosomes, Artificial, Yeast | 6 | 1.0 |
Restriction Mapping | 15 | 0.0 |
Croatia | 2 | 5.0 |
Cell Membrane/immunology | 7 | 2.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
*Corneal Transplantation | 8 | 36.0 |
Transplantation Immunology | 5 | 7.0 |
3T3 Cells | 2 | 0.0 |
Biological Transport/genetics/immunology | 2 | 25.0 |
Down-Regulation/*immunology | 2 | 3.0 |
Protein Binding/genetics/immunology | 5 | 6.0 |
B-Lymphocytes | 7 | 3.0 |
COS Cells | 2 | 0.0 |
Cytotoxicity, Immunologic | 32 | 3.0 |
HLA-B35 Antigen/genetics/*immunology | 2 | 100.0 |
Herpesvirus 4, Human | 5 | 3.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
HLA Antigens/*blood/genetics | 2 | 66.0 |
Family Health | 6 | 0.0 |
Psoriasis/*genetics/immunology | 4 | 30.0 |
B-Lymphocytes/chemistry | 2 | 8.0 |
*HIV-1 | 2 | 0.0 |
Zambia | 2 | 14.0 |
Uveitis, Anterior/*genetics | 3 | 100.0 |
Antibody Formation | 7 | 1.0 |
HLA Antigens/analysis | 34 | 13.0 |
HLA-B Antigens/*analysis/genetics | 6 | 54.0 |
*Sexual Partners | 2 | 22.0 |
HLA-C Antigens/*genetics/immunology | 2 | 66.0 |
*Histocompatibility Testing/methods | 4 | 33.0 |
Probability | 5 | 0.0 |
*Telomere | 2 | 7.0 |
Membrane Proteins/genetics | 5 | 1.0 |
Great Britain | 7 | 2.0 |
HLA Antigens/isolation & purification | 2 | 50.0 |
Kidney Transplantation/*statistics & numerical data | 5 | 50.0 |
Norway | 7 | 6.0 |
Sweden | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 41 | 1.0 |
*Indians, North American | 2 | 6.0 |
Mexico/ethnology | 4 | 14.0 |
Species Specificity | 4 | 0.0 |
HLA-B27 Antigen/blood | 6 | 75.0 |
Binding Sites/genetics/immunology | 2 | 4.0 |
Genes, MHC Class I/*immunology | 5 | 22.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
Trans-Activation (Genetics)/*immunology | 2 | 10.0 |
Syndrome | 5 | 0.0 |
Cytoplasm/chemistry/immunology | 2 | 100.0 |
*Genotype | 6 | 2.0 |
Ireland | 2 | 3.0 |
Models, Statistical | 2 | 1.0 |
Linkage (Genetics)/genetics | 4 | 1.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Phosphorylation | 4 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
*Heterozygote | 3 | 0.0 |
Indians, North American | 2 | 6.0 |
Isoelectric Focusing/methods | 5 | 17.0 |
Antigens, CD/analysis | 3 | 0.0 |
Cornea/*immunology | 4 | 33.0 |
*Transplantation Immunology | 6 | 13.0 |
Sequence Deletion | 5 | 0.0 |
HLA-A Antigens/genetics/immunology/*metabolism | 2 | 66.0 |
HLA-B Antigens/genetics/immunology/*metabolism | 3 | 100.0 |
Immunologic Surveillance | 2 | 7.0 |
India | 8 | 2.0 |
Proteins/genetics | 2 | 0.0 |
*Consanguinity | 4 | 16.0 |
*Pregnancy Outcome | 2 | 3.0 |
Arthritis, Reactive/*etiology | 2 | 100.0 |
*Asian Continental Ancestry Group | 4 | 6.0 |
*Exons | 3 | 0.0 |
*Gene Conversion | 2 | 6.0 |
*Genome, Human | 3 | 1.0 |
Open Reading Frames | 2 | 0.0 |
Statistics | 3 | 0.0 |
HLA-DP Antigens/*genetics | 5 | 6.0 |
*Introns | 4 | 1.0 |
Gene Expression/drug effects | 2 | 0.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Databases, Factual | 2 | 0.0 |
*Kidney Transplantation/immunology/statistics & numerical data | 3 | 100.0 |
*Living Donors | 2 | 10.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
HLA-B7 Antigen/*genetics | 6 | 85.0 |
*Repressor Proteins | 2 | 0.0 |
Russia | 2 | 2.0 |
Gene Conversion | 5 | 8.0 |
*Phylogeny | 5 | 2.0 |
Point Mutation | 6 | 0.0 |
Isoelectric Focusing | 10 | 1.0 |
Epitopes/chemistry/genetics | 2 | 9.0 |
In Vitro | 17 | 0.0 |
Melanoma/genetics/*immunology | 3 | 20.0 |
T-Lymphocytes/*immunology | 23 | 1.0 |
HLA-B27 Antigen/*immunology | 5 | 50.0 |
Immunogenetics | 6 | 12.0 |
Biological Markers | 8 | 0.0 |
Spondylitis, Ankylosing/genetics | 4 | 50.0 |
HLA-B Antigens/genetics/*metabolism | 3 | 75.0 |
Melanoma/*immunology/metabolism | 2 | 15.0 |
Heart Transplantation/*immunology | 6 | 9.0 |
*Histocompatibility | 13 | 25.0 |
Immunosuppressive Agents/*therapeutic use | 3 | 2.0 |
Myocardium/pathology | 3 | 3.0 |
Tacrolimus/therapeutic use | 2 | 28.0 |
Liver Transplantation/adverse effects/*immunology | 2 | 66.0 |
RNA, Viral/blood | 2 | 0.0 |
Structure-Activity Relationship | 14 | 0.0 |
Immune Tolerance | 7 | 2.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
B-Lymphocytes/immunology | 25 | 3.0 |
Binding Sites/genetics | 4 | 0.0 |
*Genes, myc | 2 | 0.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
HLA-A2 Antigen/*immunology | 2 | 9.0 |
Breast Neoplasms/*immunology | 2 | 3.0 |
Complement 2/*deficiency | 6 | 10.0 |
Genetic Screening | 3 | 0.0 |
Histocompatibility Antigens Class II/genetics | 22 | 18.0 |
Denmark/epidemiology | 2 | 3.0 |
*Serologic Tests | 3 | 30.0 |
Blood Transfusion/*adverse effects | 3 | 4.0 |
Cross-Sectional Studies | 2 | 0.0 |
HLA-D Antigens/immunology | 4 | 10.0 |
Immunization | 11 | 2.0 |
T-Lymphocytes | 4 | 1.0 |
Histocompatibility Antigens Class I/*physiology | 2 | 9.0 |
Killer Cells, Natural/immunology/metabolism | 2 | 6.0 |
HLA Antigens/genetics/*immunology | 23 | 31.0 |
Bone Marrow/*immunology | 2 | 3.0 |
*Blood Transfusion | 12 | 10.0 |
RNA, Messenger | 2 | 0.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
HLA Antigens/*genetics/metabolism | 2 | 16.0 |
HLA-A Antigens/chemistry/genetics | 2 | 100.0 |
HLA-B Antigens/chemistry/genetics | 2 | 66.0 |
HLA-C Antigens/chemistry/genetics | 2 | 100.0 |
*Recombination, Genetic | 19 | 5.0 |
Behcet Syndrome/*genetics/immunology | 5 | 71.0 |
DNA/isolation & purification | 3 | 2.0 |
HLA-C Antigens/analysis/*genetics | 4 | 66.0 |
Sequence Analysis, DNA/*methods | 2 | 3.0 |
*Evolution | 6 | 3.0 |
Selection (Genetics) | 10 | 7.0 |
*Cross Reactions | 5 | 35.0 |
*Epitopes | 13 | 9.0 |
Graft Rejection/*prevention & control | 3 | 7.0 |
Antigen-Presenting Cells/*immunology | 3 | 2.0 |
Disease Models, Animal | 3 | 0.0 |
HLA-B27 Antigen/*genetics/*immunology | 2 | 100.0 |
HLA-B7 Antigen/genetics/immunology | 2 | 100.0 |
Rats | 4 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
Graft Rejection/*etiology/immunology | 2 | 100.0 |
*Lung Transplantation | 2 | 7.0 |
Data Interpretation, Statistical | 3 | 1.0 |
HLA-B Antigens/*genetics/metabolism | 2 | 100.0 |
ATP-Binding Cassette Transporters/*physiology | 2 | 9.0 |
Drug Therapy, Combination | 4 | 0.0 |
Lymphotoxin/*genetics | 7 | 9.0 |
Heat-Shock Proteins 70/*genetics | 2 | 4.0 |
Turkey/epidemiology | 2 | 2.0 |
HLA-A Antigens/*blood | 3 | 42.0 |
HLA-B Antigens/*blood | 6 | 75.0 |
HLA-DQ Antigens/*blood | 2 | 33.0 |
HLA-DR Antigens/*blood | 2 | 10.0 |
South Africa | 5 | 3.0 |
*Adrenal Hyperplasia, Congenital | 5 | 22.0 |
Continental Population Groups | 11 | 6.0 |
Genes, Recessive | 7 | 1.0 |
Binding, Competitive | 5 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Peptides/metabolism | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Cytotoxicity, Immunologic/*genetics | 2 | 22.0 |
Histocompatibility Antigens Class I/*genetics/immunology | 4 | 15.0 |
Immunity, Natural/genetics | 2 | 3.0 |
DNA Restriction Enzymes/metabolism | 4 | 4.0 |
*Polymorphism, Restriction Fragment Length | 11 | 1.0 |
beta 2-Microglobulin/*immunology | 2 | 8.0 |
South Dakota | 3 | 60.0 |
DNA, Satellite/analysis | 2 | 6.0 |
Base Composition | 3 | 1.0 |
Genome, Human | 2 | 0.0 |
*Multigene Family | 8 | 1.0 |
Pseudogenes | 3 | 1.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
HLA-B7 Antigen/genetics/*immunology | 2 | 50.0 |
Immunity, Natural | 2 | 0.0 |
Rheumatic Heart Disease/*genetics/immunology | 2 | 100.0 |
Azathioprine/therapeutic use | 2 | 5.0 |
Graft Rejection | 20 | 13.0 |
*Pancreas Transplantation | 2 | 11.0 |
Mexico/epidemiology | 2 | 6.0 |
Pregnancy Outcome | 3 | 1.0 |
DNA/*genetics | 5 | 1.0 |
*Diagnostic Errors | 2 | 11.0 |
Diagnostic Errors | 2 | 2.0 |
Tissue and Organ Procurement/*methods | 3 | 37.0 |
DNA Probes, HLA | 9 | 47.0 |
Tissue and Organ Procurement | 2 | 9.0 |
HLA-A Antigens/*analysis/genetics | 3 | 30.0 |
Codon/*genetics | 2 | 3.0 |
Consanguinity | 5 | 1.0 |
Consensus Sequence | 8 | 1.0 |
DNA, Complementary/genetics | 5 | 0.0 |
HLA-B8 Antigen/genetics/immunology | 2 | 66.0 |
Neoplasms/immunology | 2 | 3.0 |
Precipitin Tests | 6 | 0.0 |
Tissue Distribution | 2 | 0.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
Feasibility Studies | 2 | 0.0 |
Antigenic Variation | 3 | 10.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Marriage | 2 | 8.0 |
Genome | 3 | 1.0 |
Primates | 2 | 2.0 |
HLA-DR4 Antigen/genetics | 5 | 17.0 |
DNA, Satellite/*genetics | 4 | 6.0 |
*Graft Rejection | 11 | 12.0 |
Cytomegalovirus Infections/complications | 2 | 12.0 |
HLA Antigens/classification/*genetics | 3 | 27.0 |
Islam | 2 | 18.0 |
*Indians, South American | 2 | 8.0 |
Panama | 2 | 28.0 |
Antibodies/immunology | 2 | 0.0 |
*Protein Conformation | 3 | 1.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Gene Library | 5 | 0.0 |
Diagnosis, Differential | 6 | 0.0 |
Asian Continental Ancestry Group | 5 | 1.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
*DNA Primers | 4 | 14.0 |
Isoelectric Point | 5 | 4.0 |
HLA Antigens/*blood | 4 | 14.0 |
Ischemia | 2 | 11.0 |
Renal Dialysis | 6 | 1.0 |
Tissue and Organ Procurement/*organization & administration | 3 | 27.0 |
Waiting Lists | 3 | 14.0 |
Receptors, Immunologic/*immunology | 4 | 3.0 |
Blotting, Northern | 14 | 0.0 |
Cloning, Molecular | 34 | 0.0 |
Cosmids | 5 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Herpesvirus 4, Human/*immunology | 3 | 4.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
*Antibody Specificity | 2 | 2.0 |
*Cryopreservation | 2 | 3.0 |
Lymphocyte Depletion | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
HLA-B Antigens/blood | 2 | 16.0 |
HLA Antigens/blood | 2 | 16.0 |
Kidney Transplantation/*mortality | 2 | 22.0 |
Antigens, CD8/immunology | 2 | 2.0 |
Blood Donors | 6 | 2.0 |
Blood Grouping and Crossmatching | 6 | 8.0 |
Chile | 2 | 3.0 |
Ecuador | 2 | 18.0 |
ATP-Binding Cassette Transporters/immunology | 2 | 100.0 |
Karyotyping | 4 | 0.0 |
Mutagenesis | 3 | 0.0 |
Leukocyte Count | 3 | 0.0 |
Lectins/*metabolism | 2 | 3.0 |
HLA Antigens/*metabolism | 5 | 15.0 |
Killer Cells, Natural/*metabolism | 7 | 12.0 |
*Receptors, Immunologic | 3 | 1.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Protein Binding/immunology | 3 | 1.0 |
Greece | 2 | 2.0 |
ABO Blood-Group System | 6 | 9.0 |
HLA-A Antigens/metabolism | 3 | 23.0 |
Gorilla gorilla | 3 | 7.0 |
Pan troglodytes | 6 | 4.0 |
Histocompatibility Antigens Class II/immunology | 10 | 5.0 |
Peptide Fragments/immunology | 4 | 1.0 |
Malaysia | 3 | 7.0 |
Biological Transport | 3 | 0.0 |
Cell Membrane | 2 | 3.0 |
Laryngeal Neoplasms/*immunology | 3 | 33.0 |
Signal Transduction | 4 | 0.0 |
HLA-A Antigens/analysis/*genetics | 4 | 44.0 |
HLA-B Antigens/analysis/*genetics | 7 | 50.0 |
Denmark | 4 | 2.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics | 3 | 13.0 |
Lymphotoxin/genetics | 9 | 15.0 |
Histocompatibility Antigens Class I/genetics/*physiology | 2 | 28.0 |
DNA, Recombinant | 3 | 1.0 |
HIV Infections/*immunology | 2 | 0.0 |
Macaca mulatta | 2 | 0.0 |
SIV/genetics/*immunology | 2 | 25.0 |
B-Lymphocytes/*immunology | 21 | 2.0 |
Electrophoresis/methods | 2 | 2.0 |
Base Sequence/genetics | 2 | 0.0 |
DNA, Satellite/*immunology | 2 | 66.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 4 | 8.0 |
Multiple Sclerosis/genetics/*immunology | 2 | 10.0 |
Cell Survival | 4 | 0.0 |
*Haploidy | 5 | 35.0 |
HLA-C Antigens/immunology | 4 | 19.0 |
Isoantigens/*immunology | 2 | 2.0 |
Receptors, Immunologic/*physiology | 5 | 2.0 |
Pan troglodytes/genetics | 2 | 4.0 |
Romania | 2 | 11.0 |
Fatal Outcome | 2 | 0.0 |
Liver/pathology | 2 | 1.0 |
*Oligonucleotide Probes | 2 | 8.0 |
B-Lymphocytes/cytology | 3 | 3.0 |
Tumor Cells, Cultured/immunology | 3 | 3.0 |
Antigens, Neoplasm | 2 | 5.0 |
Cell Division | 6 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Killer Cells, Natural/cytology/*immunology | 2 | 7.0 |
HLA-C Antigens/biosynthesis/*genetics | 2 | 100.0 |
Cold | 2 | 1.0 |
Complement 4a/*genetics | 3 | 8.0 |
Complement 4b/*genetics | 3 | 8.0 |
Complement Factor B/*genetics | 11 | 8.0 |
Abortion, Habitual/*immunology | 6 | 25.0 |
HLA Antigens/*physiology | 2 | 14.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
Cause of Death | 3 | 1.0 |
France | 5 | 1.0 |
Peptides/*metabolism | 2 | 1.0 |
Disease Susceptibility/immunology | 3 | 4.0 |
Diabetes Mellitus, Type 1/genetics | 2 | 5.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
HLA-B Antigens/*chemistry/genetics/immunology | 2 | 100.0 |
Epitopes/genetics | 5 | 5.0 |
Isoantigens/genetics | 2 | 10.0 |
*Lymphocyte Culture Test, Mixed | 5 | 8.0 |
Variation (Genetics)/*immunology | 2 | 33.0 |
*Blood Grouping and Crossmatching | 3 | 17.0 |
DNA/genetics/isolation & purification | 4 | 1.0 |
Indians, South American | 2 | 14.0 |
Birth Intervals | 2 | 40.0 |
Christianity | 3 | 23.0 |
Maternal-Fetal Exchange | 2 | 1.0 |
Isoantigens | 3 | 11.0 |
*DNA Fingerprinting | 2 | 4.0 |
Africa South of the Sahara | 2 | 13.0 |
Blotting, Southern | 20 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
RNA, Messenger/genetics | 11 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Interferon-alpha/*therapeutic use | 2 | 3.0 |
Epitopes/metabolism | 2 | 3.0 |
*Genetic Markers | 8 | 2.0 |
Antibodies, Monoclonal/diagnostic use | 9 | 1.0 |
*Cell Line | 2 | 4.0 |
Genes, myc | 2 | 0.0 |
HLA Antigens/analysis/genetics | 5 | 19.0 |
Nucleic Acid Hybridization/genetics | 2 | 50.0 |
Complement 4/*genetics | 17 | 12.0 |
Fathers | 2 | 3.0 |
Mass Screening | 3 | 1.0 |
Parity | 5 | 4.0 |
Paternity | 2 | 2.0 |
*Gene Expression | 2 | 0.0 |
HLA-A Antigens/biosynthesis | 3 | 33.0 |
HLA-B Antigens/biosynthesis | 3 | 30.0 |
Genes, Dominant | 6 | 0.0 |
Hemochromatosis/*genetics | 5 | 5.0 |
Heat-Shock Proteins 70/genetics | 2 | 5.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
HLA-A Antigens | 65 | 21.0 |
HLA-B Antigens | 119 | 30.0 |
HLA-B7 Antigen | 12 | 42.0 |
Epitopes/*analysis | 8 | 5.0 |
Models, Structural | 2 | 1.0 |
Glycoproteins/immunology | 2 | 2.0 |
Receptors, Immunologic/chemistry/*immunology | 2 | 100.0 |
Methylation | 5 | 0.0 |
*Heart Transplantation | 4 | 5.0 |
HLA-D Antigens/genetics | 3 | 7.0 |
Primates/genetics | 2 | 4.0 |
HLA-DQ Antigens/immunology | 5 | 12.0 |
Histocompatibility Antigens Class II/*immunology | 13 | 7.0 |
Steroid 21-Hydroxylase/genetics | 9 | 20.0 |
Histocompatibility Antigens Class I/blood/*genetics | 2 | 33.0 |
Graft Enhancement, Immunologic | 2 | 22.0 |
*Immunization | 4 | 8.0 |
Serology | 2 | 16.0 |
Graft Rejection/epidemiology | 3 | 13.0 |
Great Britain/epidemiology | 3 | 2.0 |
Organ Preservation | 3 | 13.0 |
Regression Analysis | 3 | 0.0 |
Complement/*genetics | 11 | 18.0 |
Complement 2/genetics | 6 | 12.0 |
Complement 4/genetics | 12 | 19.0 |
Reiter Disease/*genetics | 3 | 100.0 |
Antibody Affinity | 3 | 1.0 |
Isoantibodies/immunology | 6 | 14.0 |
*Alu Elements | 2 | 11.0 |
Complement/genetics | 8 | 29.0 |
Australia | 6 | 3.0 |
Graft Rejection/genetics/*immunology | 2 | 40.0 |
DNA Primers/*genetics | 2 | 20.0 |
Finland | 3 | 1.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Melanoma/*immunology | 4 | 4.0 |
Histocompatibility Testing/*standards | 2 | 28.0 |
Hemochromatosis/genetics | 2 | 5.0 |
H-2 Antigens/genetics | 2 | 8.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Receptors, Antigen, T-Cell/genetics | 3 | 3.0 |
HLA-D Antigens/*genetics | 8 | 5.0 |
Switzerland | 3 | 4.0 |
HLA Antigens/*biosynthesis/genetics | 3 | 27.0 |
HLA-C Antigens/biosynthesis | 2 | 28.0 |
Cyclosporine/pharmacology | 2 | 0.0 |
Immunoglobulin M/*immunology | 2 | 3.0 |
Kidney Transplantation/immunology | 4 | 7.0 |
Blood Platelets/*immunology | 4 | 5.0 |
*Immunologic Tests | 2 | 28.0 |
DNA/analysis/genetics | 2 | 1.0 |
Genetic Complementation Test | 3 | 0.0 |
Gestational Age | 3 | 0.0 |
*Phenotype | 3 | 1.0 |
Cytotoxicity, Immunologic/immunology | 4 | 5.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 2 | 2.0 |
HLA-DR Antigens | 53 | 15.0 |
Kidney Transplantation/*immunology/statistics & numerical data | 5 | 29.0 |
Wales | 2 | 11.0 |
Graft Rejection/prevention & control | 2 | 4.0 |
HLA-B Antigens/analysis/*immunology | 3 | 75.0 |
Antigens, Viral/immunology | 5 | 4.0 |
Influenza A virus/immunology | 2 | 15.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Lymphocytes/*immunology | 18 | 4.0 |
Fetus/*immunology | 2 | 4.0 |
Autoantibodies/genetics | 2 | 40.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Immune Sera/immunology | 3 | 1.0 |
Hypertension/etiology | 2 | 4.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
DNA, Satellite/genetics | 3 | 2.0 |
Hamsters | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
DNA Probes | 11 | 1.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Antilymphocyte Serum/pharmacology | 2 | 16.0 |
Complement Fixation Tests | 2 | 2.0 |
Graft Survival/drug effects | 2 | 6.0 |
Histocompatibility Testing/statistics & numerical data | 2 | 50.0 |
Radioimmunoassay | 2 | 0.0 |
Spondylitis, Ankylosing/genetics/*immunology | 2 | 40.0 |
Crossing Over, Genetic | 12 | 16.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
DNA Fingerprinting | 2 | 1.0 |
Pan troglodytes/*genetics | 2 | 7.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Lupus Erythematosus, Systemic/*genetics/*immunology | 2 | 13.0 |
Immunologic Techniques | 3 | 0.0 |
*Chromosomes, Fungal | 2 | 8.0 |
HLA-D Antigens/analysis | 2 | 3.0 |
*HLA Antigens | 60 | 28.0 |
L Cells (Cell Line) | 3 | 1.0 |
Immunoglobulin M/immunology | 3 | 2.0 |
Immunoglobulins, lambda-Chain/immunology | 2 | 33.0 |
HLA-DR Antigens/analysis/*immunology | 2 | 18.0 |
Mouth Diseases/*immunology | 2 | 25.0 |
Graves' Disease/*genetics/immunology | 3 | 27.0 |
*Genes, Structural | 14 | 1.0 |
Clinical Protocols | 2 | 3.0 |
Antilymphocyte Serum/*therapeutic use | 2 | 6.0 |
Cyclosporine/*therapeutic use | 2 | 6.0 |
Models, Theoretical | 2 | 1.0 |
Hyperplasia | 2 | 0.0 |
Multiple Sclerosis/*genetics | 5 | 6.0 |
Genes, Immunoglobulin | 2 | 1.0 |
Kidney/immunology | 4 | 9.0 |
Graft Survival/physiology | 2 | 12.0 |
Kidney Transplantation/immunology/*statistics & numerical data | 4 | 40.0 |
Reoperation/statistics & numerical data | 2 | 22.0 |
Histocompatibility Antigens Class I/*blood | 2 | 18.0 |
Pregnancy/*immunology | 2 | 3.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Antilymphocyte Serum/analysis | 3 | 21.0 |
HLA Antigens/analysis/classification | 2 | 40.0 |
*Transfection | 5 | 2.0 |
Epitopes/analysis | 8 | 3.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Kidney Function Tests | 3 | 2.0 |
Codon | 2 | 0.0 |
Pseudogenes/genetics | 2 | 2.0 |
Cell Differentiation | 2 | 0.0 |
HLA-DR Antigens/analysis/genetics | 3 | 11.0 |
Chromosome Deletion | 11 | 1.0 |
Epitopes/*genetics/immunology | 2 | 14.0 |
Hybridomas/immunology | 4 | 3.0 |
Antigens, CD/*analysis | 2 | 0.0 |
Intercellular Adhesion Molecule-1 | 2 | 0.0 |
Antigens, CD4/analysis | 3 | 0.0 |
Coronary Disease/etiology/*immunology/pathology | 2 | 100.0 |
Immunosuppression/adverse effects | 2 | 18.0 |
Postoperative Complications/*immunology | 2 | 12.0 |
Cell Separation | 7 | 0.0 |
*Immunogenetics | 3 | 25.0 |
Keratoplasty, Penetrating/*immunology | 3 | 50.0 |
Histocompatibility Testing/*statistics & numerical data | 2 | 40.0 |
African Americans | 3 | 2.0 |
Immunoglobulin A/*analysis | 3 | 5.0 |
Arizona | 3 | 10.0 |
Asthma/immunology | 2 | 5.0 |
Diabetes Mellitus, Type 1/immunology | 2 | 11.0 |
Cross Reactions/immunology | 2 | 4.0 |
*Paternity | 7 | 9.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Genes, Structural | 21 | 2.0 |
Heart Transplantation/*adverse effects | 2 | 14.0 |
Escherichia coli/genetics | 2 | 0.0 |
Interferons/*pharmacology | 3 | 4.0 |
Postoperative Complications | 2 | 1.0 |
Chromosome Disorders | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 2 | 0.0 |
Steroid 21-Hydroxylase/*genetics | 5 | 7.0 |
Diseases in Twins | 2 | 4.0 |
Antibodies, Anti-Idiotypic/*immunology | 2 | 4.0 |
Genes, MHC Class I/genetics | 2 | 8.0 |
Uveomeningoencephalitic Syndrome/*immunology | 2 | 50.0 |
Blood Group Antigens/genetics | 2 | 3.0 |
Spain/ethnology | 2 | 6.0 |
HLA-C Antigens/metabolism | 2 | 33.0 |
beta 2-Microglobulin/biosynthesis | 2 | 16.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Histocompatibility Antigens Class I/analysis/*genetics | 2 | 50.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Cyclosporins/therapeutic use | 13 | 34.0 |
Carcinoma, Squamous Cell/*immunology/pathology | 2 | 14.0 |
Laryngeal Neoplasms/*immunology/pathology | 2 | 50.0 |
Phytohemagglutinins/pharmacology | 4 | 0.0 |
Antigens, CD3 | 2 | 0.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 3 | 0.0 |
Receptors, IgG | 2 | 1.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Uterine Neoplasms/genetics/*immunology | 2 | 66.0 |
Skin Tests | 2 | 1.0 |
England | 4 | 3.0 |
Antigens, Surface/immunology | 5 | 2.0 |
HLA-D Antigens/*immunology | 3 | 5.0 |
Antibodies/*analysis | 2 | 1.0 |
Antigens, Surface/analysis | 5 | 1.0 |
HLA-C Antigens/*analysis/genetics/immunology | 2 | 100.0 |
beta 2-Microglobulin/analysis | 3 | 2.0 |
Models, Biological | 4 | 0.0 |
T-Lymphocytes, Helper-Inducer/immunology | 3 | 1.0 |
*Mutation | 5 | 0.0 |
Steroid Hydroxylases/*genetics | 4 | 4.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Analysis of Variance | 3 | 0.0 |
Czechoslovakia | 5 | 29.0 |
Transplantation, Isogeneic | 2 | 7.0 |
Parents | 2 | 2.0 |
Microscopy, Electron | 3 | 0.0 |
Cyclosporins/administration & dosage | 3 | 50.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Epitopes/genetics/*immunology | 4 | 28.0 |
Lymphocytes/analysis | 2 | 13.0 |
Chromatography, Gel | 2 | 0.0 |
Canada | 3 | 2.0 |
HLA-B27 Antigen | 17 | 43.0 |
HLA-A2 Antigen | 9 | 29.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
*Lymphocyte Activation/drug effects | 3 | 2.0 |
Receptors, Interleukin-2 | 2 | 1.0 |
*Lymphocyte Activation | 14 | 1.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Antigens, Surface/*genetics | 3 | 4.0 |
*Cross-Linking Reagents | 2 | 13.0 |
Cyclosporins/*therapeutic use | 7 | 28.0 |
Lymphocytes | 2 | 1.0 |
Immunosorbent Techniques | 4 | 1.0 |
African Continental Ancestry Group | 7 | 2.0 |
Boston | 2 | 14.0 |
Trinucleotide Repeats | 2 | 1.0 |
Transplantation Immunology/immunology | 2 | 40.0 |
Plasmids | 2 | 0.0 |
HLA-D Antigens/*analysis | 4 | 6.0 |
Immunoblotting | 2 | 0.0 |
Tissue Banks | 2 | 18.0 |
France/epidemiology | 2 | 1.0 |
Internet | 3 | 3.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Graft vs Host Disease/etiology | 3 | 5.0 |
HLA-B35 Antigen | 4 | 16.0 |
HLA Antigens/genetics/immunology | 2 | 6.0 |
Lupus Erythematosus, Systemic/*immunology | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Erythrocytes/*immunology | 4 | 2.0 |
*Immunity, Cellular | 7 | 5.0 |
Diabetes Mellitus, Type 1/*immunology | 4 | 5.0 |
Enzyme Precursors/*genetics | 10 | 9.0 |
Autoantibodies/immunology | 2 | 1.0 |
Islets of Langerhans/immunology | 2 | 5.0 |
Immunoglobulin Allotypes/*genetics | 2 | 9.0 |
Immunoglobulin Gm Allotypes/*genetics | 3 | 33.0 |
HLA-DR4 Antigen | 5 | 8.0 |
Blood Transfusion | 15 | 8.0 |
T-Lymphocytes/*classification | 2 | 5.0 |
*ABO Blood-Group System | 2 | 5.0 |
Cattle | 4 | 0.0 |
Swine | 3 | 0.0 |
Isoantibodies/*analysis | 2 | 8.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 2 | 4.0 |
Abortion, Habitual/genetics/*immunology | 2 | 20.0 |
Complement 4b | 3 | 3.0 |
RNA/genetics | 2 | 1.0 |
Electrophoresis | 2 | 0.0 |
Immunosuppression/methods | 4 | 12.0 |
HLA-C Antigens | 22 | 16.0 |
Autoantibodies/analysis | 4 | 2.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
Steroid Hydroxylases/*deficiency | 11 | 39.0 |
Tunicamycin/pharmacology | 2 | 2.0 |
DNA Restriction Enzymes | 7 | 1.0 |
Complement 2/*genetics | 7 | 15.0 |
Genes | 4 | 1.0 |
Lactoylglutathione Lyase/*genetics | 6 | 14.0 |
Lyases/*genetics | 6 | 12.0 |
*Graft Enhancement, Immunologic | 2 | 50.0 |
Preoperative Care | 5 | 3.0 |
Actuarial Analysis | 5 | 6.0 |
Isoantibodies/analysis | 5 | 22.0 |
Arthritis, Rheumatoid/genetics | 2 | 18.0 |
Chromosome Aberrations | 2 | 0.0 |
Complement 4a | 3 | 5.0 |
DNA Restriction Enzymes/diagnostic use | 8 | 21.0 |
*Reproduction | 2 | 10.0 |
Immunoglobulins, Fab/immunology | 3 | 2.0 |
Periodontitis/*immunology | 2 | 11.0 |
HLA-B8 Antigen | 5 | 18.0 |
HLA-DR2 Antigen | 2 | 10.0 |
HLA-DR3 Antigen | 6 | 15.0 |
HLA-DR5 Antigen | 3 | 18.0 |
*African Continental Ancestry Group | 3 | 2.0 |
beta 2-Microglobulin/immunology | 3 | 8.0 |
Erythrocytes/*analysis | 2 | 4.0 |
Ferritin/*blood | 2 | 3.0 |
Iron/blood | 2 | 2.0 |
Lactoylglutathione Lyase/genetics | 5 | 11.0 |
HLA Antigens/*classification/genetics | 2 | 50.0 |
Dengue/genetics/*immunology | 2 | 100.0 |
*HLA Antigens/genetics | 7 | 28.0 |
*HLA-A Antigens | 3 | 15.0 |
*HLA-C Antigens | 4 | 28.0 |
Interferon Type I/*pharmacology | 2 | 4.0 |
Antigen-Antibody Complex | 3 | 1.0 |
Prenatal Diagnosis | 2 | 1.0 |
*Genes, Viral | 2 | 1.0 |
Reiter Disease/genetics | 2 | 66.0 |
Adrenal Hyperplasia, Congenital/*genetics | 2 | 8.0 |
*Genes | 5 | 2.0 |
Haploidy | 28 | 23.0 |
*Chromosomes, Human, 6-12 and X | 9 | 6.0 |
Meiosis | 3 | 2.0 |
Genes, Lethal | 2 | 2.0 |
Isoantigens/*analysis | 3 | 13.0 |
Cornea/blood supply | 2 | 14.0 |
Tissue Preservation | 2 | 6.0 |
*Disease Outbreaks | 2 | 3.0 |
Electrocardiography | 2 | 0.0 |
Graves' Disease/genetics/*immunology | 2 | 22.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
17-alpha-Hydroxyprogesterone | 2 | 4.0 |
Adrenal Glands/*pathology | 2 | 33.0 |
Androgens/blood | 3 | 4.0 |
Corticotropin/diagnostic use | 4 | 18.0 |
Hydroxyprogesterones/blood | 4 | 8.0 |
Geography | 2 | 3.0 |
Cardiomyopathy, Hypertrophic/*genetics/immunology | 2 | 50.0 |
Hemolysis | 2 | 0.0 |
beta 2-Microglobulin/genetics | 2 | 9.0 |
Complement Pathway, Classical | 2 | 1.0 |
Cytotoxicity Tests, Immunologic/methods | 2 | 7.0 |
Leukemia, Lymphocytic/immunology | 2 | 7.0 |
Child Welfare | 2 | 8.0 |
Infant Welfare | 2 | 20.0 |
L Cells (Cell Line)/immunology | 2 | 13.0 |
Integrin alphaXbeta2 | 2 | 5.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Chromosomes, Human, 6-12 and X | 6 | 13.0 |
Fetus/immunology | 2 | 5.0 |
Immunoelectrophoresis | 2 | 0.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 2 | 6.0 |
Monocytes/*immunology | 4 | 0.0 |
Tuberculin/*immunology | 2 | 11.0 |
Antigen-Antibody Complex/*analysis | 2 | 1.0 |
Antibodies/analysis | 2 | 1.0 |
Blood Platelets/immunology | 3 | 4.0 |
Coombs' Test | 2 | 7.0 |
*Renal Dialysis | 3 | 0.0 |
Antibodies, Viral/analysis | 3 | 2.0 |
Blood Group Antigens/immunology | 2 | 9.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
Rosette Formation | 4 | 1.0 |
Immunoglobulin G/analysis | 4 | 1.0 |
Antibody-Dependent Cell Cytotoxicity | 2 | 2.0 |
*Histocompatibility Antigens Class II | 2 | 3.0 |
HLA-DP Antigens | 2 | 8.0 |
*Protein Biosynthesis | 3 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
HLA Antigens/analysis/*genetics | 9 | 25.0 |
Alcoholism/*genetics | 2 | 2.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Papain | 2 | 20.0 |
Germany/ethnology | 2 | 15.0 |
Glomerulonephritis, IGA/*classification/genetics/immunology/mortality | 2 | 100.0 |
Hematuria/etiology | 3 | 25.0 |
Immunoglobulin Inv Allotypes/*genetics | 2 | 66.0 |
Kidney Failure, Chronic/etiology | 3 | 11.0 |
Cornea/pathology | 2 | 22.0 |
Chemistry | 3 | 1.0 |
*Diseases in Twins | 2 | 6.0 |
Graft vs Host Reaction | 2 | 18.0 |
HLA Antigens/*isolation & purification | 5 | 38.0 |
Peptide Fragments/analysis | 3 | 1.0 |
ABO Blood-Group System/immunology | 2 | 8.0 |
Histocompatibility Antigens Class II | 3 | 6.0 |
Complement/analysis | 2 | 1.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Antibodies | 2 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
*Isoantibodies | 2 | 11.0 |
Diabetes Mellitus/genetics/*immunology | 3 | 50.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
Immunoglobulin G | 3 | 2.0 |
Protein Biosynthesis | 3 | 0.0 |
Immune Sera/pharmacology | 4 | 4.0 |
*Receptors, Fc | 2 | 28.0 |
Cell-Free System | 2 | 0.0 |
Austria | 2 | 3.0 |
*Crossing Over, Genetic | 2 | 6.0 |
Histocompatibility Antigens/*analysis | 7 | 14.0 |
Mathematics | 4 | 2.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
Uveitis/*immunology | 2 | 14.0 |
Isoantibodies | 2 | 8.0 |
*Isoantigens | 4 | 25.0 |
Seasons | 2 | 1.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Diarrhea/etiology | 2 | 11.0 |
Remission, Spontaneous | 2 | 2.0 |
Spondylitis, Ankylosing/immunology | 2 | 15.0 |
Genetics, Medical | 2 | 8.0 |
Absorption | 2 | 1.0 |
Immune Sera | 2 | 0.0 |
Precipitation | 2 | 1.0 |
*Population | 2 | 28.0 |
beta 2-Microglobulin | 2 | 28.0 |
*HLA Antigens/analysis | 14 | 40.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Spondylitis, Ankylosing/*complications/immunology | 2 | 66.0 |
*Antibody Formation | 2 | 2.0 |
*Rh-Hr Blood-Group System | 2 | 6.0 |
Mixed Function Oxygenases/*deficiency | 2 | 12.0 |
Hay Fever/*genetics | 2 | 50.0 |
Pollen | 2 | 20.0 |
Newfoundland | 3 | 21.0 |
*Histocompatibility Antigens/analysis | 4 | 26.0 |
*Complement | 2 | 3.0 |
*Histocompatibility Antigens | 23 | 31.0 |
Histocompatibility Antigens/*isolation & purification | 3 | 50.0 |
*Properdin | 2 | 50.0 |
*HLA Antigens/isolation & purification | 2 | 66.0 |
*Histocompatibility Antigens/isolation & purification | 2 | 100.0 |
Jurkat Cells | 3 | 0.0 |
